- Home
- YCBD vs APRE Comparison
YCBD vs APRE Comparison
Compare YCBD & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YCBD | APRE |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9M | 8.4M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | YCBD | APRE |
|---|---|---|
| Price | $0.78 | $0.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.00 | ★ $5.50 |
| AVG Volume (30 Days) | ★ 418.0K | 81.9K |
| Earning Date | 05-14-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.70 | N/A |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.55 |
| 52 Week High | $2.56 | $2.30 |
Technical Indicators
Market Signals| Indicator | YCBD | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 48.91 | 42.64 |
| Support Level | $0.69 | $0.55 |
| Resistance Level | $1.00 | $0.95 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 71.51 | 17.93 |
Price Performance
Historical ComparisonAbout YCBD cbdMD Inc.
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
About APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.